Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
REPL Stock Forecast 2026-2027
$9.52
Current Price
$828.54M
Market Cap
Buy 2
Hold 5
Sell 1
Wall St Analyst Ratings
Distance to REPL Price Targets
+78.6%
To High Target of $17.00
+5.0%
To Median Target of $10.00
-79.0%
To Low Target of $2.00
REPL Price Momentum
-13.4%
1 Week Change
-4.8%
1 Month Change
-23.8%
1 Year Change
-2.1%
Year-to-Date Change
-28.1%
From 52W High of $13.24
+534.7%
From 52W Low of $1.50
📊 TOP ANALYST CALLS
Did REPL Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Replimune is one of their latest high-conviction picks.
Latest REPL Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, REPL has a neutral consensus with a median price target of $10.00 (ranging from $2.00 to $17.00). The overall analyst rating is Buy (6.3/10). Currently trading at $9.52, the median forecast implies a 5.0% upside. This outlook is supported by 2 Buy, 5 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
REPL Analyst Ratings
2
Buy
5
Hold
1
Sell
REPL Price Target Range
Low
$2.00
Average
$10.00
High
$17.00
Current: $9.52
Latest REPL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for REPL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 30, 2026 | Wedbush | Robert Driscoll | Neutral | Maintains | $9.00 |
| Jun 1, 2026 | Wedbush | Neutral | Maintains | $N/A | |
| Apr 13, 2026 | Cantor Fitzgerald | Neutral | Downgrade | $N/A | |
| Apr 13, 2026 | Leerink Partners | Market Perform | Downgrade | $N/A | |
| Apr 13, 2026 | JP Morgan | Underweight | Downgrade | $N/A | |
| Apr 13, 2026 | Wedbush | Neutral | Downgrade | $N/A | |
| Apr 13, 2026 | Jefferies | Hold | Downgrade | $N/A | |
| Apr 13, 2026 | HC Wainwright & Co. | Sell | Downgrade | $N/A | |
| Feb 5, 2026 | Piper Sandler | Overweight | Maintains | $N/A | |
| Feb 4, 2026 | Wedbush | Outperform | Maintains | $N/A | |
| Nov 3, 2025 | BMO Capital | Market Perform | Upgrade | $N/A | |
| Oct 27, 2025 | HC Wainwright & Co. | Buy | Upgrade | $N/A | |
| Oct 20, 2025 | JP Morgan | Neutral | Upgrade | $N/A | |
| Oct 20, 2025 | Leerink Partners | Outperform | Upgrade | $N/A | |
| Oct 20, 2025 | Wedbush | Outperform | Upgrade | $N/A | |
| Sep 19, 2025 | JP Morgan | Underweight | Downgrade | $N/A | |
| Sep 8, 2025 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| Jul 30, 2025 | Cantor Fitzgerald | Overweight | Upgrade | $N/A | |
| Jul 23, 2025 | BMO Capital | Underperform | Downgrade | $N/A | |
| Jul 23, 2025 | Barclays | Equal-Weight | Downgrade | $N/A |
Replimune Group Inc. (REPL) Competitors
The following stocks are similar to Replimune based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Replimune Group Inc. (REPL) Financial Data
Replimune Group Inc. has a market capitalization of $828.54M with a P/E ratio of -2.9x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -107.9%.
Valuation Metrics
Market Cap
$828.54M
Enterprise Value
$765.25M
P/E Ratio
-2.9x
PEG Ratio
-9.5x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+33.6%
Current Ratio
4.8x
Debt/Equity
67.2x
ROE
-107.9%
ROA
-45.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Replimune Group Inc. (REPL) Business Model
About Replimune Group Inc.
What They Do
Develops oncolytic immunotherapies for cancer treatment.
Business Model
The company focuses on creating and commercializing innovative treatments using oncolytic viruses that specifically target and destroy cancer cells while activating the immune response. It generates revenue through the development of its proprietary product candidates, which are designed to address various solid tumors, and aims to partner with larger biopharmaceutical companies for distribution and commercialization.
Additional Information
Founded in 2015 and based in Woburn, Massachusetts, Replimune Group Inc. is positioned within the oncology sector, leveraging advanced viral mechanisms to enhance patient outcomes in cancer care. Its lead product candidates, RP1, RP2, and RP3, represent a novel approach to harnessing the immune system in the fight against cancer.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
479
CEO
Dr. Sushil Patel Ph.D.
Country
United States
IPO Year
2018
Website
www.replimune.comReplimune Group Inc. (REPL) Latest News & Analysis
Latest News
Quick Summary
Johnson Fistel, PLLP is investigating potential claims against Replimune Group, Inc. (NASDAQ: REPL) officers and directors for alleged fiduciary duty breaches affecting long-term shareholders.
Why It Matters
The investigation could indicate potential legal and financial risks for Replimune Group, affecting shareholder value and confidence in management.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update
18 days ago
Quick Summary
Replimune Group, Inc. (Nasdaq: REPL) reported financial results for Q4 and the fiscal year ending March 31, 2026, and provided a business update on its oncolytic immunotherapy developments.
Why It Matters
Replimune's financial results and business updates signal its progress in oncolytic immunotherapies, potentially influencing investor confidence and stock performance in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Replimune Group faces an FDA AdCom for RP1, following two rejections. A decision is due by August 2, 2026. RP1 shows a 34% ORR in melanoma. REPL stock has risen over 135% since April.
Why It Matters
Replimune's upcoming FDA AdCom and potential approval of RP1 could significantly impact its stock value, especially after recent gains and prior rejections, reflecting market volatility and sentiment.
Source: Seeking Alpha
Market Sentiment:
Positive
Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma
21 days ago
Quick Summary
Replimune Group's BLA resubmission for RP1 combined with nivolumab for advanced melanoma has been accepted for FDA review, a significant development for the company.
Why It Matters
The FDA's acceptance of Replimune's BLA resubmission for RP1 boosts prospects for approval, potentially leading to increased market value and investor interest in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Replimune Group, Inc. (NASDAQ: REPL) presented 3-year survival data from the IGNYTE trial for RP1 plus nivolumab in melanoma patients at the 2026 ASCO meeting.
Why It Matters
The presentation of 3-year survival data from a key clinical trial can significantly impact Replimune's stock price and investor confidence, indicating potential for treatment approval and market success.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Replimune Group, Inc. (NASDAQ: REPL) presented final first-in-human data for RP2, alone and with nivolumab, in advanced solid tumors at the 2026 ASCO annual meeting.
Why It Matters
Replimune's promising data on RP2's efficacy in advanced solid tumors could boost its stock value and attract investment in the biotech sector focused on innovative cancer treatments.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About REPL Stock
What is Replimune Group Inc.'s (REPL) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, Replimune Group Inc. (REPL) has a median price target of $10.00. The highest price target is $17.00 and the lowest is $2.00.
Is REPL stock a good investment in 2027?
According to current analyst ratings, REPL has 2 Buy ratings, 5 Hold ratings, and 1 Sell ratings. The stock is currently trading at $9.52. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for REPL stock?
Wall Street analysts predict REPL stock could reach $10.00 in the next 12 months. This represents a 5.0% increase from the current price of $9.52. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Replimune Group Inc.'s business model?
The company focuses on creating and commercializing innovative treatments using oncolytic viruses that specifically target and destroy cancer cells while activating the immune response. It generates revenue through the development of its proprietary product candidates, which are designed to address various solid tumors, and aims to partner with larger biopharmaceutical companies for distribution and commercialization.
What is the highest forecasted price for REPL Replimune Group Inc.?
The highest price target for REPL is $17.00 from at , which represents a 78.6% increase from the current price of $9.52.
What is the lowest forecasted price for REPL Replimune Group Inc.?
The lowest price target for REPL is $2.00 from at , which represents a -79.0% decrease from the current price of $9.52.
What is the overall REPL consensus from analysts for Replimune Group Inc.?
The overall analyst consensus for REPL is neutral. Out of 3 Wall Street analysts, 2 rate it as Buy, 5 as Hold, and 1 as Sell, with a median price target of $10.00.
How accurate are REPL stock price projections?
Stock price projections, including those for Replimune Group Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 3:10 AM UTC